Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 4, 2009, Pages 297-304

  Imran, Farhan ^a   Phatak, Pradyumna ^a  

^a ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Cost effectiveness; Deferasirox; Deferoxamine; Hemochromatosis; Iron overload; Myelodysplastic syndrome; Sickle cell disease; Thalassemia

Indexed keywords

DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE; HEMOSIDERIN; HEPCIDIN; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; BETA THALASSEMIA; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; CATARACT; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEALTH CARE COST; HEARING LOSS; HEMOCHROMATOSIS; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NAUSEA; OVERALL SURVIVAL; OXIDATION; PHARMACODYNAMICS; PHLEBOTOMY; POSTMARKETING SURVEILLANCE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RETINA DISEASE; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; ANEMIA; ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; ERYTHROCYTE TRANSFUSION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHARMACOECONOMICS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANEMIA; BENZOIC ACIDS; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; ERYTHROCYTE TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MEDICATION ADHERENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES;

EID: 70350464321     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.26     Document Type: Review

References (39)

1. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 95(1), 26-36 (1996).
2. Olivieri NF. The β-thalassemias. N. Engl. J. Med. 341(2), 99-109 (1999).
3. Pippard MJ, Warner GT, Callender ST, Weatherall DJ. Iron absorption and loading in β-thalassemia intermedia. Lancet 2(8147), 819-821 (1979).
4. Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23(30), 7594-7603 (2005). (Pubitemid 46291823)
5. Armand P, Kim HT, Cutler CS et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109(10), 4586-4588 (2007). (Pubitemid 46743431)
6. Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am. J. Hematol. 83(8), 611-613 (2008)
7. Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120(2), 187-200 (2003). (Pubitemid 36194166)
8. Bennett JM. MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am. J. Hematol. 83(11), 858-861 (2008).
9. Pietrangelo A, Brissot P, Bonkovsky H et al. Design of an ongoing Phase I-II open label, dose escalation trial using the oral chelator deferasirox to treat iron overload in HFE-related hereditary hemochromatosis (HH). Blood 109(11), 788a (2007).
10. Arboretti R, Tognoni G, Alberti D. Italian Colaborative Group on Thalassaemia. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur. J. Clin. Pharmacol. 56(12), 915-922 (2001).
11. Cohen A. Management of iron overload in the pediatric patient. Hematol. Oncol. Clin. North Am. 1 (3), 521-544 (1987). (Pubitemid 18087564)
12. Payne K, Desrosiers M, Caro J et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 47(10), 1820-1829 (2007).
13. Nick H, Acklin P, Lattmann R et al. Development of tridentate iron chelators: From desferrithiocin to ICL670. Curr. Med. Chem. 10(12), 1065-1076 (2003). (Pubitemid 36582249)
14. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Séchaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J. Clin. Pharmacol. 43(6), 565-572 (2003). (Pubitemid 36613115)
15. Piga A, Galanello R, Forni GL et al. Randomized Phase II trial of deferasirox (exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91(7), 873-880 (2006). (Pubitemid 44023139)
16. Cappellini MD, Cohen A, Piga A et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107(9), 3455-3462 (2006). • Landmark Phase III trial establishing efficacy and safety of deferasirox in patients with β-thalassemia.
17. Vichinsky E, Onyekwere O, Porter J et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br. J. Haematol. 136(3), 501-508 (2007). (Pubitemid 46046309)
18. Leitch H, Leger C, Goodman T et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin. Leuk. 2(3), 205-211 (2008).
19. Metzgeroth G, Dinter D, Schultheis B et al. Deferasirox in MDS patients with transfusion-caused iron overload - a Phase-II study. Ann. Hematol. 88(4), 301-310 (2008).
20. Porter J, Galanello R, Saglio G et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur. J. Haematol. 80(2), 168-176 (2008).
21. Cappellini M, El-Beshlawy A, Kattamis A et al. Efficacy and safety of deferasirox (Exjade® ) in patients with transfusion-dependent anemias: 1-year results from the large, prospective, multicenter EPIC study. American Society of Hematology 50th Annual Meeting abstracts. Blood 112(11), 1319 (2008).
22. McLeod C, Fleeman N, Kirkham J et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol. Assess. 13(1), iii-iv, ix-xi, 1-121 (2009).
23. Delea TE, Thomas SK, Baldi JF, Coates TD. Once dailyoral deferasirox (Exjade® , ICL670) versus infusional deferoxamine as iron chelation therapy in patients with sickle-cell disease receiving frequent transfusions: a cost-effectiveness analysis. Blood 106, 5584 (2005).
24. Delea TE, Thomas SK, Baladi JF, Phatak PD. Cost-effectiveness analysis of oral iron chelation therapy with deferasirox (Exjade® , ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic syndrome. Blood 106, 5585 (2005).
25. Delea TE, El Ouagari K, Sofrygin O. Cost of current iron chelation infusion therapy and cost effectiveness of once-daily oral deferasirox in transfusion-dependent thalassemia patients in Canada. Presented at: American Society of Hematology 48th Annual Meeting, FL, USA, 3349 (2006).
26. Delea T, Sofrygin O, Thomas S, Baladi JF, Phatak P, Coates TD. Cost-effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassemia patients: US healthcare system perspective. Pharmacoeconomics 25, 329-342 (2007). • Most detailed cost-effectiveness analysis of deferasirox versus deferoxamine from a US healthcare system perspective. (Pubitemid 46607383)
27. Delea TE, Sofrygin O, Baladi J-F et al. Sensitivity analysis on the cost-effectiveness of chelation therapy with deferasirox or deferoxamine in transfusion dependent thalassemia patients based on European costs. Presented at: European Hematology Association 11th Annual Congress. Amsterdam, The Netherlands, 15-18 June 2006.
28. Calebro A, Delea TE, Sofrygin O et al. Cost-effectiveness of once-daily oral chelation therapy with deferasirox (Exjade® ) versus infusional deferoxamine in transfusion dependent thalassemic patients: a Brazilian perspective. Presented at: European Hematology Association 11th Annual Congress. Amsterdam, The Netherlands, 15-18 June 2006.
29. Karnon J, Akehurst R, Papo N. Cost utility analysis of deferasirox (Exjade® ) versus deferoxamine (Desferal) for patients requiring iron chelation therapy in the United Kingdom. Presented at: European Hematology Association 11th Annual Congress. Amsterdam, The Netherlands, 15-18 June 2006.
30. Karnon J, Akehurst R, Jewitt K, Ossa D. Cost utility analysis of deferasirox (Exjade® ) versus deferoxamine (Desferal) for patients requiring iron chelation therapy in the United Kingdom. Presented at: European Hematology Association 12th Annual Congress. Vienna, Austria, 7-10 June 2007.
31. Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr. Med. Res. Opin. 24(6), 1609-1621 (2008). (Pubitemid 351929059)
32. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making 13(4), 322-338 (1993).
33. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br. J. Haematol. 121(6), 938-948 (2003). (Pubitemid 36760315)
34. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch. Intern. Med. 163(14), 1637-1641 (2003).
35. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol. 73(3), 403-409 (1989).
36. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Myelodysplastic Syndromes. v.1.2009 www.nccn.org/ professionals/physician-gls/PDF/mds.pdf (Accessed December 2008)
37. Ferriprox® International Website www.ferriprox.com/worldwide/default. asp (Accessed May 2009)
38. Full prescribing information Exjade®. Novartis Pharmaceuticals Corporation. East Hanover, New Jersey 07936 Rev: October 2008 www.pharma.us.novartis.com/product/pi/ pdf/exjade.pdf (Accessed December 2008)
39. MedWatch 2007. The FDA Safety Information and Adverse Event Reporting Program www.fda.gov/medwatch/safety/2007/ safety07.htm#Exjade (Accessed December 2008)